2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年 度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 证券代码：688098 证券简称：申联生物公告编号：2026-007 申联生物医药（上海）股份有限公司 单位：人民币 万元 ■ 注：1．本报告期初数同法定披露的上年年末数。 2．每股收益、每股净资产计算时发行在外的总股本以扣减回购专用账户中的股份后的股本数为准。以 上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准。 3．以上数据若有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 1、报告期的经营情况、财务状况 报告期内，公司实现营业收入28,826.65万元，较上年减少4.99%；归属于母公司所有者的净利 润-1,909.07万元，较上年减亏57.33%。 报告期末，总资产为15 ...

Core Viewpoint - The company expects a net profit of approximately -20 million yuan for the year 2025, which represents a reduction in losses of about 24.74 million yuan compared to the previous year, indicating a year-on-year loss reduction of approximately 55% [1] Group 1: Financial Performance - The company's net profit attributable to the parent company and the net profit after deducting non-recurring gains and losses are both expected to show losses for 2025 [1] - The overall sales revenue and gross margin have slightly decreased compared to the same period last year due to intense competition in the animal health industry and a decline in vaccine product prices [1] - The increase in accounts receivable due to delayed customer payments has led to a rise in credit impairment losses [1] - The depreciation of fixed assets has increased following the commissioning of a new vaccine workshop [1] Group 2: Strategic Developments - The company is actively expanding into new areas of biopharmaceutical technology and optimizing its marketing layout, resulting in increased product sales volume [1] - The company has made significant progress in the research and development of multi-valent vaccines, with new products such as the swine fever genetic engineering subunit vaccine and the swine streptococcus disease/infectious pleuropneumonia bivalent vaccine being launched [1] - The total period expenses have significantly decreased compared to the previous year, contributing to a reduction in net profit losses by approximately 55% [1] Group 3: Investment and Future Plans - The company has invested in a stake in the innovative drug company Yangzhou Shizhi Yuan Biotechnology Co., Ltd., which is conducting clinical research on innovative drugs [2] - The company plans to acquire a controlling stake in Shizhi Yuan to synergize its human and animal health businesses, leveraging its advanced biotechnology and production advantages in the human innovative drug sector [2] - The company aims to expedite the research and development and market launch of several innovative drugs, including monoclonal antibodies for AIDS [2]

智通财经APP讯，申联生物(688098.SH)发布2025年年度业绩预告，预计2025年度实现归属于母公司所 有者的净利润约-2,000万元，与上年同期相比，减少亏损约2,474万元，亏损幅度同比收窄约55%。 报告期初，公司投资参股创新药公司扬州世之源生物科技有限责任公司(以下简称"世之源")，世之源正 在开展创新药的临床研究并进行持续投入，对公司净利润造成一定影响。为全面实现人药和动保双主业 协同发展的模式，公司拟收购世之源的控股权，未来公司将以世之源作为新型生物医药技术及人用创新 药推进平台，充分发挥公司前沿生物技术及生产优势在人用创新药领域的延展应用，快速推进艾滋病单 抗等多个创新药的研发及上市。 在此情况下，公司适时调整经营策略，市场拓展进一步聚焦客户需求，多联多价疫苗等产品研发取得积 极进展，猪瘟基因工程亚单位疫苗、猪链球菌病/传染性胸膜肺炎二联疫苗等产品接连上市，产品种类 更加丰富;内部管理更加精干高效，期间费用总额较上年同期明显下降，归属母公司净利润亏损减少约 55%。 报告期内，公司归属于母公司所有者的净利润和归属于母公司所有者的扣除非经常性损益的净利润出现 亏损，主要基于以下原因：202 ...

Core Viewpoint - The company Shunlian Bio has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its genetically engineered subunit vaccine for swine fever, along with the issuance of the veterinary drug product approval number [1] Group 1 - The approval signifies a significant milestone for the company's product development in the veterinary vaccine sector [1] - The vaccine is expected to enhance the company's market position in the animal health industry [1] - This development may lead to increased revenue opportunities for the company in the future [1]

Core Viewpoint - The city of Hohhot is striving to become the leading hub for veterinary vaccine research and production in China, driven by significant technological breakthroughs and supportive policies in the biopharmaceutical industry [1][3][5] Group 1: Technological Breakthroughs - Jin Yu Bao Ling Biopharmaceutical Co., Ltd. launched the "Jin Niu Zhi" vaccine, marking a major technological advancement in China's biopharmaceutical sector [1] - The company has also established an intelligent manufacturing line capable of producing 8 million doses of pet vaccines annually, which has passed GMP static acceptance [1] - The establishment of the Inner Mongolia Animal Vaccine Technology Innovation Center aims to enhance vaccine research and development, focusing on major animal diseases [2][3] Group 2: Industry Growth and Collaboration - Hohhot has seen its biopharmaceutical industry output grow from 13.11 billion yuan in 2020 to 20.25 billion yuan in 2024, with 117 research institutions and 602 drug registration approvals [4] - The city has actively collaborated with prestigious institutions like the Chinese Academy of Sciences and Tsinghua University to accelerate vaccine development [4] - The introduction of high-value product projects by local companies aims to enhance the quality and innovation of animal serum and vaccine production [2][4] Group 3: Policy Support and Investment - Hohhot has implemented various policies to support the high-quality development of the biopharmaceutical industry, including financial incentives totaling 14 million yuan for innovation platforms and vaccine projects [3] - The city is positioning itself as a national leader in veterinary vaccine production, with significant investments in research and development infrastructure [5] - The establishment of the National Swine Technology Innovation Center in Inner Mongolia signifies the region's commitment to becoming a key player in the animal vaccine industry [4]